Nycomed files MAA for Diatide's AcuTect

Article

Peptide imaging agent developer Diatide of Londonderry, NH, reported last month that its marketing partner, Nycomed Amersham, has submitted Diatide's AcuTect product for regulatory review by European authorities. Nycomed, of Buckinghamshire, U.K.,

Peptide imaging agent developer Diatide of Londonderry, NH, reported last month that its marketing partner, Nycomed Amersham, has submitted Diatide's AcuTect product for regulatory review by European authorities. Nycomed, of Buckinghamshire, U.K., submitted a marketing approval application (MAA) for the product to the European Medicines Evaluation Agency. Nycomed has informed Diatide that it hopes to gain approval for AcuTect in the next 12 months.

AcuTect, formerly known as P280, is a technetium-labeled product for the detection and localization of acute venous thrombosis. Diatide filed a new drug application (NDA) for AcuTect with the Food and Drug Administration in September. The NDA was granted a priority rating, meaning that the agency intends to complete its review in six months.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.